210 results on '"Tam, Henry"'
Search Results
202. Diagnostic Performance of 68 Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer.
- Author
-
Light A, Lazic S, Houghton K, Bayne M, Connor MJ, Tam H, Ahmed HU, Shah TT, and Barwick TD
- Subjects
- Male, Humans, Gallium Radioisotopes, Positron Emission Tomography Computed Tomography, Retrospective Studies, Multiparametric Magnetic Resonance Imaging, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms radiotherapy
- Abstract
For men with prostate cancer who develop biochemical failure after radiotherapy, European guidelines recommend reimaging with
68 Ga-PSMA-11 PET/CT and multiparametric MRI (mpMRI). However, the accuracy of68 Ga-PSMA-11 PET/CT for detecting intraprostatic recurrences is unclear, both with and without mpMRI. Methods: A single-center retrospective study of a series of patients investigated for radiorecurrence between 2016 and 2022 is described. All patients underwent68 Ga-PSMA-11 PET/CT, mpMRI, and prostate biopsy. PET/CT images were interpreted independently by 2 expert readers masked to other imaging and clinical data. The primary outcome was the diagnostic accuracy of PET/CT versus mpMRI and of PET/CT with mpMRI together versus mpMRI alone. The secondary outcome was the proportion of cancers missed by mpMRI but detected by PET/CT. Diagnostic accuracy analysis was performed at the prostate hemigland level using cluster bootstrapping. Results: Thirty-five men (70 hemiglands) were included. Cancer was confirmed by biopsy in 43 of 70 hemiglands (61%). PET/CT sensitivity and negative predictive values (NPVs) were 0.89 (95% CI, 0.78-0.98) and 0.79 (95% CI, 0.62-0.95), respectively, which were not significantly different from results by MRI (sensitivity of 0.72; 95% CI, 0.61-0.83; P = 0.1) (NPV of 0.59; 95% CI, 0.41-0.75; P = 0.07). Specificity and positive predictive values were not significantly different. When PET/CT and MRI were used together, the sensitivity was 0.98 (95% CI, 0.92-1.00) and NPV was 0.93 (95% CI, 0.75-1.00), both significantly higher than MRI alone ( P = 0.003 and P < 0.001, respectively). Specificity and positive predictive values remained not significantly different. MRI missed 12 of 43 cancers (28%; 95% CI, 17%-43%), of which 11 of 12 (92%; 95% CI, 62%-100%) were detected by PET/CT. Conclusion: For detecting intraprostatic radiorecurrence,68 Ga-PSMA-11 PET/CT has high sensitivity that is not significantly different from mpMRI. When68 Ga-PSMA-11 PET/CT and mpMRI were used together, the results conferred a significantly greater sensitivity and NPV than with mpMRI alone.68 Ga-PSMA-11 PET/CT may therefore be a useful tool in the diagnosis of localized radiorecurrence., (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2024
- Full Text
- View/download PDF
203. Bench to Bedside Development of [ 18 F]Fluoromethyl-(1,2- 2 H 4 )choline ([ 18 F]D4-FCH).
- Author
-
Challapalli A, Barwick TD, Dubash SR, Inglese M, Grech-Sollars M, Kozlowski K, Tam H, Patel NH, Winkler M, Flohr P, Saleem A, Bahl A, Falconer A, De Bono JS, Aboagye EO, and Mangar S
- Subjects
- Male, Humans, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography methods, Radiometry, Choline metabolism, Prostatic Neoplasms pathology
- Abstract
Malignant transformation is characterised by aberrant phospholipid metabolism of cancers, associated with the upregulation of choline kinase alpha (CHKα). Due to the metabolic instability of choline radiotracers and the increasing use of late-imaging protocols, we developed a more stable choline radiotracer, [
18 F]fluoromethyl-[1,2-2 H4 ]choline ([18 F]D4-FCH). [18 F]D4-FCH has improved protection against choline oxidase, the key choline catabolic enzyme, via a1 H/2 D isotope effect, together with fluorine substitution. Due to the promising mechanistic and safety profiles of [18 F]D4-FCH in vitro and preclinically, the radiotracer has transitioned to clinical development. [18 F]D4-FCH is a safe positron emission tomography (PET) tracer, with a favourable radiation dosimetry profile for clinical imaging. [18 F]D4-FCH PET/CT in lung and prostate cancers has shown highly heterogeneous intratumoral distribution and large lesion variability. Treatment with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer patients elicited mixed responses on PET at 12-16 weeks despite predominantly stable radiological appearances. The sum of the weighted tumour-to-background ratios (TBRs-wsum) was associated with the duration of survival.- Published
- 2023
- Full Text
- View/download PDF
204. Rethinking prostate cancer screening: could MRI be an alternative screening test?
- Author
-
Eldred-Evans D, Tam H, Sokhi H, Padhani AR, Winkler M, and Ahmed HU
- Subjects
- Decision Trees, Humans, Male, Early Detection of Cancer methods, Magnetic Resonance Imaging, Prostatic Neoplasms diagnostic imaging
- Abstract
In the past decade rigorous debate has taken place about population-based screening for prostate cancer. Although screening by serum PSA levels can reduce prostate cancer-specific mortality, it is unclear whether the benefits outweigh the risks of false-positive results and overdiagnosis of insignificant prostate cancer, and it is not recommended for population-based screening. MRI screening for prostate cancer has the potential to be analogous to mammography for breast cancer or low-dose CT for lung cancer. A number of potential barriers and technical challenges need to be overcome in order to implement such a programme. We discuss different approaches to MRI screening that could address these challenges, including abbreviated MRI protocols, targeted MRI screening, longer rescreening intervals and a multi-modal screening pathway. These approaches need further investigation, and we propose a phased stepwise research framework to ensure proper evaluation of the use of a fast MRI examination as a screening test for prostate cancer.
- Published
- 2020
- Full Text
- View/download PDF
205. Use of Imaging to Optimise Prostate Cancer Tumour Volume Assessment for Focal Therapy Planning.
- Author
-
Eldred-Evans D, Tam H, Smith APT, Winkler M, and Ahmed HU
- Subjects
- Humans, Male, Multiparametric Magnetic Resonance Imaging, Neoplasm Staging, Patient Care Planning, Patient Selection, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms pathology, Prostatic Neoplasms therapy, Prostatic Neoplasms diagnostic imaging, Tumor Burden
- Abstract
Purpose of Review: Rapid advances in imaging of the prostate have facilitated the development of focal therapy and provided a non-invasive method of estimating tumour volume. Focal therapy relies on an accurate estimate of tumour volume for patient selection and treatment planning so that the optimal energy dose can be delivered to the target area(s) of the prostate while minimising toxicity to surrounding structures. This review provides an overview of different imaging modalities which may be used to optimise tumour volume assessment and critically evaluates the published evidence for each modality., Recent Findings: Multi-parametric MRI (mp-MRI) has become the standard tool for patient selection and guiding focal therapy treatment. The current evidence suggests that mp-MRI may underestimate tumour volume, although there is a large variability in results. There remain significant methodological challenges associated with pathological processing and accurate co-registration of histopathological data with mp-MRI. Advances in different ultrasound modalities are showing promise but there has been limited research into tumour volume estimation. The role of PSMA PET/CT is still evolving and further investigation is needed to establish if this is a viable technique for prostate tumour volumetric assessment. mp-MRI provides the necessary tumour volume information required for selecting patients and guiding focal therapy treatment. The potential for underestimation of tumour volume should be taken into account and an additional margin applied to ensure adequate treatment coverage. At present, there are no other viable image-based alternatives although advances in new technologies may refine volume estimations in the future.
- Published
- 2020
- Full Text
- View/download PDF
206. A prospective analysis of robotic targeted MRI-US fusion prostate biopsy using the centroid targeting approach.
- Author
-
Miah S, Servian P, Patel A, Lovegrove C, Skelton L, Shah TT, Eldred-Evans D, Arya M, Tam H, Ahmed HU, and Winkler M
- Subjects
- Humans, Magnetic Resonance Imaging, Male, Prospective Studies, Ultrasonography, Image-Guided Biopsy methods, Prostate pathology, Robotic Surgical Procedures methods
- Abstract
Robotic prostate biopsy is an emerging technology. Recent development of this tool has allowed the performance of a transperineal prostate biopsy allowing pre-programmed standardized biopsy schemes. Prospective data collection was undertaken in 86 consecutive men who underwent robotically assisted transperineal prostate biopsy. All underwent a multi-parametric MRI pre-biopsy with centroid targeting followed by systematic template prostate biopsy. For the purposes of this study, our definition of clinically significant prostate cancer (csPCa) is any Gleason score > 6. Mean (SD) age, median (IQR) PSA, and median (IQR) prostate volume were 64.24 (6.97) years, of 7.79 ng/ml (6.5) and 45.06 cc (28), respectively. Overall, 44 (51.2%) men were diagnosed with csPCa. csPCa was detected in the targeted biopsies alone in 35 (40.1%) men. The addition of the 12-zone template biopsy increased the yield of csPCa for another 9 (10.5%) men. Of these 9 men, the majority (7) harbored primary pattern 3 disease and only 1 was identified to have high-grade disease. Out of these 9 men, 7 of them had the identification of csPCa in the sector, where a target was contained within that zone. Robotic-assisted prostate biopsy in our study has demonstrated a high detection of csPCa when combined with limited near-field sampling. Our study suggests the use of more accurate biopsy schemes such as ring-targeting of lesions to mitigate against systematic and random mathematical errors. Adoption of this tool and biopsy strategy would potentially avoid the increased morbidity associated with whole gland systematic unguided biopsies.
- Published
- 2020
- Full Text
- View/download PDF
207. Discovery of pre-therapy 2-deoxy-2- 18 F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients.
- Author
-
Arshad MA, Thornton A, Lu H, Tam H, Wallitt K, Rodgers N, Scarsbrook A, McDermott G, Cook GJ, Landau D, Chua S, O'Connor R, Dickson J, Power DA, Barwick TD, Rockall A, and Aboagye EO
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung therapy, Female, Humans, Lung Neoplasms therapy, Male, Middle Aged, Survival Analysis, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Fluorodeoxyglucose F18, Image Processing, Computer-Assisted, Lung Neoplasms diagnostic imaging, Positron Emission Tomography Computed Tomography
- Abstract
Purpose: The aim of this multi-center study was to discover and validate radiomics classifiers as image-derived biomarkers for risk stratification of non-small-cell lung cancer (NSCLC)., Patients and Methods: Pre-therapy PET scans from a total of 358 Stage I-III NSCLC patients scheduled for radiotherapy/chemo-radiotherapy acquired between October 2008 and December 2013 were included in this seven-institution study. A semi-automatic threshold method was used to segment the primary tumors. Radiomics predictive classifiers were derived from a training set of 133 scans using TexLAB v2. Least absolute shrinkage and selection operator (LASSO) regression analysis was used for data dimension reduction and radiomics feature vector (FV) discovery. Multivariable analysis was performed to establish the relationship between FV, stage and overall survival (OS). Performance of the optimal FV was tested in an independent validation set of 204 patients, and a further independent set of 21 (TESTI) patients., Results: Of 358 patients, 249 died within the follow-up period [median 22 (range 0-85) months]. From each primary tumor, 665 three-dimensional radiomics features from each of seven gray levels were extracted. The most predictive feature vector discovered (FVX) was independent of known prognostic factors, such as stage and tumor volume, and of interest to multi-center studies, invariant to the type of PET/CT manufacturer. Using the median cut-off, FVX predicted a 14-month survival difference in the validation cohort (N = 204, p = 0.00465; HR = 1.61, 95% CI 1.16-2.24). In the TESTI cohort, a smaller cohort that presented with unusually poor survival of stage I cancers, FVX correctly indicated a lack of survival difference (N = 21, p = 0.501). In contrast to the radiomics classifier, clinically routine PET variables including SUV
max , SUVmean and SUVpeak lacked any prognostic information., Conclusion: PET-based radiomics classifiers derived from routine pre-treatment imaging possess intrinsic prognostic information for risk stratification of NSCLC patients to radiotherapy/chemo-radiotherapy.- Published
- 2019
- Full Text
- View/download PDF
208. IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.
- Author
-
Palmieri C, Szydlo R, Miller M, Barker L, Patel NH, Sasano H, Barwick T, Tam H, Hadjiminas D, Lee J, Shaaban A, Nicholas H, Coombes RC, and Kenny LM
- Subjects
- Aged, Aged, 80 and over, Breast Neoplasms metabolism, Early Detection of Cancer, Female, Humans, Middle Aged, Positron-Emission Tomography, Postmenopause, Radiopharmaceuticals administration & dosage, Receptors, Estrogen metabolism, Steryl-Sulfatase antagonists & inhibitors, Sulfonic Acids pharmacology, Treatment Outcome, Breast Neoplasms diagnostic imaging, Breast Neoplasms drug therapy, Sulfonic Acids administration & dosage, Vascular Endothelial Growth Factor Receptor-1 metabolism
- Abstract
Background: Steroid sulfatase (STS) is involved in oestrogen biosynthesis and irosustat is a first generation, irreversible steroid sulfatase inhibitor. A pre-surgical window-of-opportunity study with irosustat was undertaken in estrogen receptor-positive (ER+) breast cancer to assess the effect of irosustat on tumour cell proliferation as measured by 3'-deoxy-3'-[18F] fluorothymidine uptake measured by PET scanning (FLT-PET) and Ki67., Methods: Postmenopausal women with untreated ER+ early breast cancer were recruited, and imaged with FLT-PET at baseline and after at least 2 weeks treatment with irosustat, 40 mg once daily orally. The primary endpoint was changed in FLT uptake; secondary endpoints included safety and tolerability of irosustat, changes in tumoral Ki67 and steroidogenic enzymes expression and circulating steroid hormone levels., Results: Thirteen women were recruited, and ten started irosustat for 2 weeks, followed by repeat FLT-PET scans in eight. Defining response as decreases of ≥20% in standardized uptake value (SUV) or ≥30% in Ki, 1 (12.5% (95% CI 2-47%, p = 0.001)) and 3 (43% (95% CI 16-75%, p = <0.001) patients, respectively, responded. 6 out of 7 patients had a Ki67 reduction (range = -19.3 to 76.4%), and median percentage difference in Ki67 was 52.3% (p = 0.028). In one patient with a low baseline STS expression, a 19.7% increase in Ki67 was recorded. STS decreases were seen in tumours with high basal STS expression, significant decreases were also noted in aromatase, and 17β-hydroxysteroid dehydrogenase type 1 and 2. Irosustat was generally well tolerated with all adverse event CTCAE Grade ≤2., Conclusions: Irosustat resulted in a significant reduction in FLT uptake and Ki67, and is well tolerated. These data are the first demonstrating clinical activity of irosustat in early breast cancer. Baseline expression of STS may be a biomarker of sensitivity to irosustat.
- Published
- 2017
- Full Text
- View/download PDF
209. Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma.
- Author
-
Cheung AH, Lam CS, Tam HS, Cheung TT, Pang R, and Poon RT
- Subjects
- Aged, Antibiotics, Antineoplastic adverse effects, Carcinoma, Hepatocellular blood, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Chi-Square Distribution, Doxorubicin adverse effects, Female, Hong Kong, Humans, Kaplan-Meier Estimate, Liver Neoplasms blood, Liver Neoplasms mortality, Liver Neoplasms pathology, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Retrospective Studies, Time Factors, Tomography, X-Ray Computed, Treatment Outcome, Tumor Burden, alpha-Fetoproteins metabolism, Antibiotics, Antineoplastic administration & dosage, Carcinoma, Hepatocellular therapy, Chemoembolization, Therapeutic adverse effects, Doxorubicin administration & dosage, Liver Neoplasms therapy
- Abstract
Background: Chemoembolization with doxorubucin-eluting beads (DEB) has been used to treat hepatocellular carcinoma (HCC) since 2007. This study compared the efficacy and survival between transarterial chemoembolization (TACE) with DEB and conventional approach (cTACE) in HCC treatment., Methods: This retrospective case-control study compared the overall survival and tumor response of HCC patients to cTACE (n=190) and DEB (n=143) by the reassessment of computed tomography and serum alpha-fetoprotein (AFP). Multivariate analysis was used to determine the factors affecting tumor response., Results: The median post-treatment to pre-treatment AFP level was 0.8 for a DEB session (n=258) and 1.0 for a cTACE session (n=452), showing a significantly greater decrease in AFP after DEB (P<0.05). More patients in the DEB group achieved objective response (complete and partial) compared with those in the cTACE group (P<0.05). Objective tumor response after DEB vs cTACE was 34.8% vs 15.4% in 0-3 months (P=0.001), 37.1% vs 20.0% in 3-6 months (P<0.05), and 50.0% vs 30.0% in 6-12 months (P=0.093). DEB predicted a 3.604 times odds of achieving at least one objective tumor response in a patient when compared to cTACE (P<0.0001). The median survival from first transcatheter therapy of patients having undergone at least once DEB was 12.53 months, while those having received cTACE only was 10.53 months (P=0.086). A tendency of improved survival appeared to maintain until >80 months after the first TACE session in the DEB group., Conclusion: DEB is a safe alternative to cTACE in HCC patients with better therapeutic efficacy.
- Published
- 2016
- Full Text
- View/download PDF
210. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy.
- Author
-
Bozzette SA, Ake CF, Tam HK, Phippard A, Cohen D, Scharfstein DO, and Louis TA
- Subjects
- Adult, Anti-HIV Agents adverse effects, Anti-HIV Agents therapeutic use, Cardiovascular Diseases etiology, Cohort Studies, Female, Follow-Up Studies, HIV Infections complications, Humans, Male, Middle Aged, Retrospective Studies, Survival Rate trends, Time Factors, United States, Antiretroviral Therapy, Highly Active, Cardiovascular Diseases mortality, HIV Infections drug therapy, Veterans statistics & numerical data
- Abstract
There is continuing interest in the longer term effects of highly active antiretroviral therapy (HAART) on the risk of cardiopulmonary events. We assessed this using updated administrative data from an open retrospective cohort of HIV-infected persons receiving care from the US Veterans Affairs (VA). Information on 41,213 HIV-infected patients receiving VA care between January 1993 and December 2003 was included. Patients were followed for an average of 4 years or 168,213 person-years of follow-up. The death rate fell from 20.9 deaths per 100 patient-years of observation in 1995 to 5.2 deaths per 100 patient-years in 2003. In patient-level analysis, adjusted hazard ratios for death dropped precipitously for all races to a low of 0.18 (95% confidence interval: 0.15 to 0.23) at 72 months of exposure to HAART. Hazards for serious cardiovascular events remained near 1.0 for exposure to HAART, and hazards for serious cardiovascular events, stroke, or death were only slightly higher than for death alone. No selection effects or secular trends were found. The benefits of HAART continued to increase in the 8 years after introduction and with 6 years of individual use. The risk of serious cardiovascular events should be factored into individual patient management but does not pose an important public health risk.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.